July 30, 2026, 8:00 AM PT | 11:00 AM ET
AI is transforming antibody discovery, but better models only come from better data. When you are generating and screening sequences at scale, you need characterization results that are fast, comprehensive, and ready to use without hours of cleanup and reformatting.
Biointron built its gene-to-data platform exactly for this. Using mammalian cell expression, we deliver expression, affinity, and developability data in an integrated, high-throughput workflow that keeps up with the pace of AI-driven discovery. More data per cycle, faster turnaround, and the quality your models actually need to improve.
In this webinar, we will show you how it works and what it looks like in practice.
Learn more here: https://www.biointron.com/rushdata
Lei Shi, PhD. is Senior Vice President of Biointron. He has more than 20 years of experience in antibody discovery. Previously, Lei worked for a number of pharmaceutical and biotech companies such as Johnson & Johnson with increasing responsibilities. He completed his postdoc research at MGH and Harvard Medical School and has an Executive Master's degree from the University of Pennsylvania.
The antibody therapeutics sector is rapidly evolving, transitioning from traditi……
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured e……
ScientistとScience Exchangeとのご利用可能です。